1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al: Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation2020, 141:e139-e596.
2. Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ: Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis2020, 63:10-21.
3. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A: Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation2000, 102:2243-2248.
4. Liu Y, Lu H, Zhang C, Hu J, Xu D: Recent advances in understanding the roles of T cells in pressure overload-induced cardiac hypertrophy and remodeling. J Mol Cell Cardiol2019, 129:293-302.
5. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P: Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol2010, 298:R1089-1097.
6. Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol2005, 6:345-352.
7. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL: T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension2012, 59:324-330.
8. Katsuki M, Hirooka Y, Kishi T, Sunagawa K: Decreased proportion of Foxp3+ CD4+ regulatory T cells contributes to the development of hypertension in genetically hypertensive rats. J Hypertens2015, 33:773-783; discussion 783.
9. Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL: Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol2010, 298:H938-944.
10. Cui C, Fan J, Zeng Q, Cai J, Chen Y, Chen Z, Wang W, Li SY, Cui Q, Yang J, et al: CD4(+) T-Cell Endogenous Cystathionine γ Lyase-Hydrogen Sulfide Attenuates Hypertension by Sulfhydrating Liver Kinase B1 to Promote T Regulatory Cell Differentiation and Proliferation. Circulation2020, 142:1752-1769.
11. Wang H, Hou L, Kwak D, Fassett J, Xu X, Chen A, Chen W, Blazar BR, Xu Y, Hall JL, et al: Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression. Hypertension2016, 68:114-122.
12. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, et al: Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation2009, 119:2904-2912.
13. Iulita MF, Duchemin S, Vallerand D, Barhoumi T, Alvarez F, Istomine R, Laurent C, Youwakim J, Paradis P, Arbour N, et al: CD4(+) Regulatory T Lymphocytes Prevent Impaired Cerebral Blood Flow in Angiotensin II-Induced Hypertension. J Am Heart Assoc2019, 8:e009372.
14. Lee DL, Sturgis LC, Labazi H, Osborne JB, Jr., Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW: Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol2006, 290:H935-940.
15. Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, Tao L, Sun H, Kellems RE, Blackburn MR, Xia Y: Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension2012, 59:136-144.
16. Kimura A, Kishimoto T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol2010, 40:1830-1835.
17. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM: Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity2006, 24:677-688.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol1986, 57:450-458.
19. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol2019, 16:182-241.
20. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al: Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr2015, 28:1-39.e14.
21. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohé C, Doevendans PA: Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol2006, 26:1524-1530.
22. van Eickels M, Grohé C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA: 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation2001, 104:1419-1423.
23. Patten RD, Pourati I, Aronovitz MJ, Alsheikh-Ali A, Eder S, Force T, Mendelsohn ME, Karas RH: 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail2008, 14:245-253.
24. Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P: Age of menopause and impact of climacteric symptoms by geographical region. Climacteric2010, 13:419-428.
25. Kassan M, Wecker A, Kadowitz P, Trebak M, Matrougui K: CD4+CD25+Foxp3 regulatory T cells and vascular dysfunction in hypertension. J Hypertens2013, 31:1939-1943.
26. Li M, Wang X, Fu W, He S, Li D, Ke Q: CD4+CD25+Foxp3+ regulatory T cells protect endothelial function impaired by oxidized low density lipoprotein via the KLF-2 transcription factor. Cell Physiol Biochem2011, 28:639-648.
27. Radwan E, Mali V, Haddox S, El-Noweihi A, Mandour M, Ren J, Belmadani S, Matrougui K: Treg cells depletion is a mechanism that drives microvascular dysfunction in mice with established hypertension. Biochim Biophys Acta Mol Basis Dis2019, 1865:403-412.
28. Mian MO, Barhoumi T, Briet M, Paradis P, Schiffrin EL: Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens2016, 34:97-108.
29. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL: T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension2011, 57:469-476.
30. Trott DW, Thabet SR, Kirabo A, Saleh MA, Itani H, Norlander AE, Wu J, Goldstein A, Arendshorst WJ, Madhur MS, et al: Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertension2014, 64:1108-1115.
31. Kassan M, Galan M, Partyka M, Trebak M, Matrougui K: Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol2011, 31:2534-2542.
32. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol2008, 8:523-532.
33. Matrougui K, Abd Elmageed Z, Kassan M, Choi S, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Kadowitz P, Belmadani S, Partyka M: Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol2011, 178:434-441.
34. Turner JA, Stephen-Victor E, Wang S, Rivas MN, Abdel-Gadir A, Harb H, Cui Y, Fanny M, Charbonnier LM, Fong JJH, et al: Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity. Immunity2020, 53:1202-1214.e1206.
35. Haribhai D, Williams JB, Jia S, Nickerson D, Schmitt EG, Edwards B, Ziegelbauer J, Yassai M, Li SH, Relland LM, et al: A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity2011, 35:109-122.
36. Marie JC, Letterio JJ, Gavin M, Rudensky AY: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med2005, 201:1061-1067.
37. Saraiva M, Vieira P, O'Garra A: Biology and therapeutic potential of interleukin-10. J Exp Med2020, 217.
38. Tang TT, Yuan J, Zhu ZF, Zhang WC, Xiao H, Xia N, Yan XX, Nie SF, Liu J, Zhou SF, et al: Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol2012, 107:232.
39. Lai NC, Gao MH, Tang E, Tang R, Guo T, Dalton ND, Deng A, Tang T: Pressure overload-induced cardiac remodeling and dysfunction in the absence of interleukin 6 in mice. Lab Invest2012, 92:1518-1526.
40. Chen F, Chen D, Zhang Y, Jin L, Zhang H, Wan M, Pan T, Wang X, Su Y, Xu Y, Ye J: Interleukin-6 deficiency attenuates angiotensin II-induced cardiac pathogenesis with increased myocyte hypertrophy. Biochem Biophys Res Commun2017, 494:534-541.
41. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H: Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension2010, 56:879-884.
42. Zhao L, Cheng G, Jin R, Afzal MR, Samanta A, Xuan YT, Girgis M, Elias HK, Zhu Y, Davani A, et al: Deletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction. Circ Res2016, 118:1918-1929.
43. Shi W, Ma H, Liu T, Yan D, Luo P, Zhai M, Tao J, Huo S, Guo J, Li C, et al: Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice. 2020, 24:4748-4761.
44. Assadi F: C-reactive protein and incident left ventricular hypertrophy in essential hypertension. Pediatr Cardiol2007, 28:280-285.
45. Monfared A, Salari A, Kazemnezhad E, Lebadi M, Khosravi M, Mehrjardi NK, Rahimifar S, Amini N: Association of left ventricular hypertrophy with high-sensitive C-reactive protein in hemodialysis patients. Int Urol Nephrol2013, 45:1679-1686.
46. Vaĭda LS, Lozyns'ka NV: [The relation of structural and functional status of the left chambers of the heart, the level of circulating NT-pro-BNP and the status of endothelium dependent vasodilation with characteristics of 24 hour blood pressure monitoring in patients with arterial hypertension]. Lik Sprava2013:16-24.
47. Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi OM, Sliwa K: The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects. Cardiovasc J Afr2014, 25:233-238.
48. Jiang T, Zhao Q: Scolopendra subspinipes mutilans L. Koch Ameliorates Rheumatic Heart Disease by Affecting Relative Percentages of CD4(+)CD25(+)FoxP3 Treg and CD4(+)IL17 T Cells. 2019, 2019:4674190.
49. Jin Y, Xu H, Wu M, Yi B, Zhu M, Zhou Y, Wang J: Correlation of gestational hypertension with abnormal lipid metabolism, insulin resistance and D-dimer and their clinical significance. Exp Ther Med2019, 17:1346-1350.
50. Zicha J, Kunes J, Devynck MA: Abnormalities of membrane function and lipid metabolism in hypertension: a review. Am J Hypertens1999, 12:315-331.
51. Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, Isenovic ER: Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci2015, 52:70-85.
52. Li Q, Wang Y, Wang Y, Zhou Q, Chen K, Wang YM, Wei W, Wang Y: Distinct different sensitivity of Treg and Th17 cells to Fas-mediated apoptosis signaling in patients with acute coronary syndrome. Int J Clin Exp Pathol2013, 6:297-307.
53. Li Q, Wang Y, Li H, Shen G, Hu S: Ox-LDL influences peripheral Th17/Treg balance by modulating Treg apoptosis and Th17 proliferation in atherosclerotic cerebral infarction. Cell Physiol Biochem2014, 33:1849-1862.
54. Wagner NM, Brandhorst G, Czepluch F, Lankeit M, Eberle C, Herzberg S, Faustin V, Riggert J, Oellerich M, Hasenfuss G, et al: Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity (Silver Spring)2013, 21:461-468.
55. Tackling G, Borhade MB: Hypertensive Heart Disease. In StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021